Patents Examined by Robert S Cabral
  • Patent number: 11401463
    Abstract: The present invention concerns a luminescent particle comprising a nanoparticle of formula A1-xLnxVO4(1-y)(PO4)y??(I) in which A is selected from yttrium (Y), gadolinium (Gd), lanthanum (La), and mixtures thereof; Ln is selected from europium (Eu), dysprosium (Dy), samarium (Sm), neodymium (Nd), erbium (Er), ytterbium (Yb), and mixtures thereof; 0<x<1; and 0?y<1; characterized in that the nanoparticle on its surface has tetraalkylammonium cations in an amount such that said nanoparticle has a zeta potential, ?, of less than or equal to ?28 mV in an aqueous medium with a pH?5, more particularly with a pH?5.5, and with an ionic conductivity >100 ?S·cm?1. It also concerns a method for preparing such luminescent particles, a colloidal suspension of these particles, and the use thereof as a diagnostic agent, and also a diagnostic kit comprising such luminescent particles.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 2, 2022
    Assignees: ECOLE POLYTECHNIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Thierry Gacoin, Maximilian Richly, Pascal Preira, Antigoni Alexandrou, Cédric Bouzigues, Rabei Mohammedi
  • Patent number: 11389396
    Abstract: Methods are taught for treating chronic wounds and skin and soft tissue infections with antibiotic tumescent injection. In such methods, the region of tumescent drug delivery is monitored and expanded by the infusate in order to be 2×-5× larger in area and volume in the region of the wound or infection, the drug in the infusate creates a tissue concentration greater than the MIC in the tumescent volume for selected period of time, and the high concentration has a residence lifetime in the tissue long enough to kill the bacteria. Typically, the methods are performed without the use of vasoconstrictors such as epinephrine and in a manner that avoids physical manipulation of the wound.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: July 19, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: John Koulakis, Seth J. Putterman, James C. Dunn, Joshua Rouch, Nhan Huynh
  • Patent number: 11383008
    Abstract: The present invention relates to an efficient method for grafting a properties-imparting compound onto a polymeric substrate containing carbon-hydrogen (C—H) bonds using clip chemistry. The method of the invention includes coating the substrate with the properties-imparting compound and irradiating it with a reactive light source, and repeating this sequence at least once. The present invention further relates to surface-modified polymeric substrates grafted with a properties-imparting compound, in particular obtained with the method of the invention, medical devices comprising same, and non-medical of said surface-modified polymeric substrates.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: July 12, 2022
    Assignees: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Benjamin Nottelet, Anita Schulz épouse Luxenhofer, Jean Coudane
  • Patent number: 11369695
    Abstract: The present invention relates to the use of lipid/fat droplet deposits in retinas of a human subject as a biomarker for diagnosing, prognosing, and/or monitoring retinal neurodegeneration with or without an elevated intraocular pressure in glaucoma.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: June 28, 2022
    Assignee: The Jackson Laboratory
    Inventors: Simon W. M. John, Peter Alexander Williams
  • Patent number: 11364262
    Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided having various concentrations for different tissue types and infection levels. Compositions may be provided in gel form, and may include nanoparticle encapsulated molecules for controlled release.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 21, 2022
    Assignee: WIAB WATER INNOVATION AB
    Inventor: Geir Hermod Almås
  • Patent number: 11344494
    Abstract: The present invention provides an impregnated porous carrier material comprising at least one active pharmaceutical ingredient (API) impregnated throughout the internal surface of a porous carrier. The present invention further provides immediate release and sustained release pharmaceutical dosage forms comprising the impregnated porous carrier material disclosed herein such that any single active pharmaceutical ingredient (API) content variability in the finished drug product has a relative standard deviation of less than 3%.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: May 31, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Fernando J. Muzzio, Benjamin J. Glasser, Plamen I. Grigorov
  • Patent number: 11344638
    Abstract: The invention provides a compound having the following structure: T-DOTA-R, wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: May 31, 2022
    Inventor: Robert Norman Taub
  • Patent number: 11318073
    Abstract: The present invention is directed to a foaming composition comprising from about 5% to about 13% total surfactant of one or more anionic surfactants; from 0.1% to about 2% of a surfactant soluble antidandruff active; from about 3% to about 15% of a blowing agent, wherein the foaming composition is at a pH of about 3.5 to 6.5.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: May 3, 2022
    Assignee: The Procter and Gamble Company
    Inventors: Sean Michael Renock, Eric Scott Johnson, Debora W. Chang, Sumanth Narahari Jamadagni
  • Patent number: 11298379
    Abstract: Compositions including anti-viral compositions, therapeutic compositions, sunscreen compositions, skin treatment compositions, anti-aging compositions, and methods of making the same, are provided. Each composition includes milk fat globules (MFG) and may contain one or more agents encapsulated by the MFG. The unique nature of MFG provides an intact mammalian membrane containing proteins, glycoproteins, and carbohydrates found in mammary cells. By treating an infected patient with MFG, the MFG serve as a surrogate cell and interact with enveloped viruses, such as the COVID-19 coronavirus, the Herpes virus, and the Epstein Barr Virus, rendering them non-infectious. MFG derived from mammals can also be used to deliver pharmaceutical materials into an animal body such that the pharmaceutical materials bypass the venous blood and enter directly into the animal's lymphatic system. MFG allow the delivery of materials orally that could not heretofore have been delivered efficiently.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: April 12, 2022
    Inventor: James F. Kane
  • Patent number: 11298309
    Abstract: Methods of protecting skin of a mammal by application of silk-derived compositions useful for treating or preventing a wide variety of skin conditions. Silk solutions and silk mats are prepared and applied to the skin surface. The silk compositions may be self-adhesive or sutured to cover a wound or area of skin exposed to physical stresses and strains, thereby preventing a wound and/or promoting wound healing.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 12, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Ken Liechty, Sudipta Seal, Swetha Barkam
  • Patent number: 11291737
    Abstract: An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 5, 2022
    Assignee: CORNELL UNIVERSITY
    Inventors: Ulrich B. Wiesner, Kai Ma, Carlie Mendoza
  • Patent number: 11285211
    Abstract: It has been discovered that iron-platinum ferromagnetic particles can be dispersed in a polymer and coated into or onto, or directly linked to or embedded on to, medical devices and magnetized. The magnetized devices are used to attract, capture, and/or retain magnetically labeled cells on the surface of the device in vivo. The magnetic particles have an iron/platinum core. Annealing the Fe/Pt particle is very important for introducing a L10 interior crystalline phase. The Fe:Pt molar ratio for creation of the crystal phase is important and a molar range of 1.2-3.0 Fe to Pt (molar precursors, i.e. starting compounds) is desired for magnetization. The magnetic force as a whole can be measured with a “Super Conducting Quantum Interference Device”, which is a sensitive magnetometer. The overall magnetic force is in the range from 0.1 to 2.0 Tesla.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: March 29, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Tarek Fahmy, Albert Sinusas, Jung Seok Lee, Dongin Kim, Anthony Mathur, John Martin
  • Patent number: 11262355
    Abstract: A system for measuring analyte concentrations has porous-walled nanocontainers containing multiple magnetic nanoparticles, the magnetic nanoparticles coated with a selective binder that is analyte-responsive and binds a the analyte, an indicator substance releasable from the selective binder by the analyte, or an indicator substance cleavable by the analyte, apparatus for exposing the nanocontainers to a fluid potentially containing the analyte, and magnetic spectroscopy of Brownian motion sensing apparatus for detecting agglutination of the nanoparticles or binding of analyte to the nanoparticles.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: March 1, 2022
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: John B. Weaver, Barjor Gimi, Karl Griswold
  • Patent number: 11254701
    Abstract: The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and/or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: February 22, 2022
    Assignee: APERTA BIOSCIENCES, LLC
    Inventors: Carlos Santos, Iuan-Bor Chen, Josue Moran
  • Patent number: 11252958
    Abstract: Provided is an antimicrobial non-isotactic polymer based hard or semi-flexible surface in a thermoset and/or thermoplastic resin matrix wherein the active antimicrobial ingredient is copper oxide. Processes for preparing the same and applications thereof are also described.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Cupron, Inc.
    Inventors: Kenneth Gauthier Trinder, II, Vikram Kanmukhla
  • Patent number: 11246833
    Abstract: A method of producing an extruded, powdered/granulated composition comprising an active pharmaceutical ingredient (API), by the steps of providing an API and a porous inorganic excipient, and processing them by an extrusion process to directly produce an extruded, powdered/granulated composition wherein the API is at least partially absorbed within the pores of the inorganic excipient. In preferred embodiments, the API is melted, or solubilised in a solubilizer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: February 15, 2022
    Assignees: Cubic Pharmaceuticals Ltd., Delta Pharmaceuticals Ltd.
    Inventors: Dennis Douroumis, Mohammed Maniruzzaman, Saumil Kiritkumar Bhatt, Anwar Ali, Arun Jangra
  • Patent number: 11246950
    Abstract: A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 15, 2022
    Assignee: GALERA LABS, LLC
    Inventors: Robert A. Beardsley, Jeffery L. Keene, Dennis P. Riley
  • Patent number: 11246863
    Abstract: Disclosed herein are otic product kits for administration of a sterilized formulation. In some embodiments, the otic product kit comprises: an aseptic container containing the sterilized formulation; a syringe; and an administration needle connectable to the syringe, wherein the sterilized formulation comprising: from about 5.5 wt % to about 6.5 wt % multiparticulate ciprofloxacin; from about 15 wt % to about 17 wt % poloxamer 407; and water. Also disclosed herein are methods of preparing and administrating the sterilized formulation. In some embodiments, the method comprising (1) transferring the sterilized otic formulation from an aseptic container to a syringe through a preparation needle; (2) replacing the preparation needle with an administration needle; and (3) injecting the sterilized otic formulation from the syringe through the administration needle into the ear of a patient.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 15, 2022
    Assignee: ALK-ABELLÓ, INC.
    Inventors: Scott H. Coleman, Wei-Cheng Liaw, Jerry Wroblewski, Robert Savel
  • Patent number: 11234908
    Abstract: The present invention relates to novel oil-in-water pumpable nanoemulsions. The oil phase contains oil selected from the group consisting of triglyceride oil and/or petrolatum as well as C8 to C18 fatty acid; and the aqueous phase contains sulfoalkyl ester and/or amide of fatty acids as emulsifier.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: February 1, 2022
    Assignee: CONOPCO, INC.
    Inventors: Congling Quan, David John Lang, Bruce Davis Casbarro
  • Patent number: 11234931
    Abstract: A self-foaming composition is described that includes brimonidine, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and brimonidine or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 1, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade